Hematological Neoplasm

Product: Evoltra® Clofarabine

Disease: Acute Lymphoblastic Leukaemia (ALL)

Indication: Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response.

Product: Campath ® Alemtuzumab

Disease: B-cell Chronic Lymphocytic Leukemia (B-CLL)

Indication: Indicated as a single agent for the treatment of B-cell chronic lzmphocytic leukemia (B-CLL).

Product: Thalidomide

Disease: Multiple Myeloma

Indication: In combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged ? 65 years or ineligible for high dose chemotherapy.

Product: Oncaspar® Pegaspargase

Disease: Acute Lymphoblastic Leukemia (ALL)

Indication: Indicated as a component of a multi-agent chemotherapeutic regimen for treatment of patients with Acute lymphoblastic leukemia (ALL)

Product: Cladribine

Disease: Hairy Cell Leukaemia

Indication: Treatment of hairy cell leukaemia

Product:Thyrogen ®thyrotropin alfa for injection

Disease: Thyroid Cancer

Indication:             Indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer.

Indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.